(OTCQB:HEPA) ("Hepion" or the "Company"), a biotechnology company developing a portfolio of diagnostic and therapeutic candidates for serious liver, immune, and inflammatory diseases, today announced ...
Aquestive Therapeutics is upgraded to a Buy, anticipating Anaphylm approval and potential >$250m annual revenue by 2030. Click to read more on AQST.
Sidley represented Aquestive Therapeutics, Inc. (Nasdaq: AQST) in an exclusive license agreement and a supply agreement with Eton Pharmaceuticals, Inc. (Nasdaq: ETON) for Libervant® (diazepam) buccal ...
Eton Pharmaceuticals secures exclusive U.S. rights to Libervant, a diazepam buccal film for epilepsy seizure clusters. Read ...
Eton and Aquestive announce exclusive licensing for LIBERVANT, a buccal film for seizure clusters, launching April 2027 ...
Eton Pharmaceuticals, Inc. et Aquestive Therapeutics, Inc. ont annoncé avoir conclu un accord exclusif de licence ainsi qu’un accord d’approvisionnement couvrant les États-Unis et ...
Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
Acquisition adds GV104, a clinical-stage opioid countermeasure with a 505(b)(2) pathway and an active investigational new ...
Under the agreement, Eton will obtain exclusive rights to commercialize LIBERVANT in the United States and its territories, while Aquestive will continue to manufacture and supply the product. Eton ...
Aquestive Therapeutics (AQST) stock rises as the company inks a license deal with Eton Pharmaceuticals (ETON) for its ...
Eton Pharmaceuticals, Inc. and Aquestive Therapeutics, Inc. announced that they have entered into an exclusive license agreement and a supply agreement covering the United States and its territories ...
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results